23 results
PRE 14A
HLVX
HilleVax Inc
12 Apr 24
Preliminary proxy
4:05pm
committee reviews our policies with respect to risk assessment, risk management, loss prevention, cybersecurity, and regulatory compliance. Oversight
424B5
HLVX
HilleVax Inc
20 Sep 23
Prospectus supplement for primary offering
4:01pm
the prespecified safety assessment by the clinical trial’s data monitoring committee. In December 2022, we reported positive interim immunogenicity
424B5
ypvyk141reypluwsahcm
19 Sep 23
Prospectus supplement for primary offering
4:18pm
DEF 14A
kntjx rpizm98kyyd
28 Apr 23
Definitive proxy
4:32pm
8-K
EX-99.1
lkqgrqz67
10 Aug 22
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
4:20pm
10-Q
r64ui
8 Jun 22
Quarterly report
4:25pm
8-K
EX-99.1
lzc1u8h bild
8 Jun 22
HilleVax Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
4:16pm
424B4
x83cv03
29 Apr 22
Prospectus supplement with pricing info
4:02pm
S-1/A
jkxqdhlsiz
18 Apr 22
IPO registration (amended)
6:08am
S-1
74j37l bch
6 Apr 22
IPO registration
4:21pm
S-1
EX-10.10
vkbxcfab
6 Apr 22
IPO registration
4:21pm